Axsome Therapeutics Inc.
Axsome Therapeutics Receives FDA Priority Review for Alzheimer's Disease Agitation Treatment
Summary
On December 31, 2025, Axsome Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for its supplemental New Drug Application for the treatment of Alzheimer's Disease Agitation. Additionally, the company received formal pre-New Drug Application (NDA) meeting minutes from the FDA for its planned NDA submission for AXS-12 in narcolepsy, which supports the Company's planned NDA submission in January 2026.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement